LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.

@article{Chen2012LY294002EC,
  title={LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.},
  author={Lingchao Chen and Lei Han and Zhendong Shi and Kailiang Zhang and Yanwei Liu and Yongri Zheng and Tao Jiang and Peiyu Pu and Chuanlu Jiang and Chunsheng Kang},
  journal={Molecular medicine reports},
  year={2012},
  volume={5 2},
  pages={575-9}
}
The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas. However, a considerable number of glioblastoma (GBM) cases are refractory to TMZ. Previous studies have revealed that the PI3K/Akt pathway is activated in an ataxia telangiectasia and Rad3 related-dependent manner in response to TMZ. Thus, we hypothesized that PI3K inhibitors may act as antitumor agents against gliomas and potentiate the cytotoxicity of TMZ. The cytotoxicity of a PI3K inhibitor, LY294002… CONTINUE READING